Earlier intensive BP lowers cardiovascular events

Sustained early intensive systolic BP control reduces cardiovascular events in older hypertensive adults; delaying initiation attenuates benefit. Multicenter randomized controlled trial with extended follow-up; Level 1b (2011 OCEBM).

Background

The durability and timing of benefit from intensive systolic blood pressure targets in older adults have been unclear.

Patients

  • 8,511 adults, age 60–80 years, hypertension; China; 42 centers.
  • Baseline SBP ~146 mm Hg; groups well balanced.

Intervention

Intensive SBP target 110–<130 mm Hg (sustained from randomization).

Control

Standard SBP target 130–<150 mm Hg during original trial, then switched to intensive in extension (delayed intensive).

Outcome

Primary: composite of stroke, acute coronary syndrome, acute heart failure, coronary revascularization, atrial fibrillation, or cardiovascular death. Safety prespecified (e.g., hypotension).

Follow up period

Median 6.11 years (original trial to Dec 31, 2020; intensive extension Jan 2021–Jul 31, 2023).

Results

Outcome Sustained Intensive Delayed Intensive Effect (95% CI) Absolute Difference NNT/NNH
Primary composite (primary) 6.83% 8.11% HR 0.82 (0.71–0.96) −1.28% NNT 78 (≈6.1 y)
Stroke (secondary) 2.12% 2.91% HR 0.72 (0.55–0.94) −0.79% NNT 127
Hypotension (safety) 3.82% 2.81% RR 1.36 (1.07–1.72) +1.01% NNH 99
Modeled primary risk: start intensive at 0 mo 7.18% 8.68% (standard) RR 0.83 (0.70–0.96) −1.49% NNT 68
Modeled primary risk: start at 12 mo 7.63% 8.68% (standard) RR 0.88 (0.76–0.99) −1.05% NNT 96

Limitations

  • Han Chinese cohort; generalizability may be limited.
  • Open-label BP targets; potential management bias (endpoints blinded).
  • 9% declined extension; selection bias possible.
  • g-formula estimates assume no model misspecification.
  • No all-cause mortality difference detected; limited power.

Funding

Chinese national and Beijing municipal public grants; minimal commercial bias.

Citation

Song Q, Peng X, Bai J, et al. Intensive Blood Pressure Control in Older Patients With Hypertension: 6-Year Results of the STEP Trial. J Am Coll Cardiol. 2025;86(17):1421–1433. doi:10.1016/j.jacc.2025.06.045.